Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 1997

View Archived Issues

Indian investigators prepare novel hypolipidemic agents

Novel LTB4 receptor antagonist described

Schering AG investigates vitamin D derivatives

SKB prepares chimeric leptins

Antitumor heterocyclic compounds from Takeda

Akzo reports peptides for specific tolerance therapy

Zambon discloses ACE/NEP inhibitors

Antifungals from Schering-Plough

PFT inhibitors described by Warner-Lambert

Biorex discloses antiischemic agents

Subtype-selective 5-HT1 antagonists from Pierre Fabre

Anergen reports 1996 financial results

InSite Vision releases 1996 earnings

Interneuron announces first-quarter fiscal 1997 results

Targeted Genetics reports fourth-quarter 1996 financial results

Schering-Plough seeks FDA approval for psoriasis treatment

Xytronyx reports fiscal 1997 third-quarter results

Cortex seeks AMPAkine patent approval

Vasogen to extend clinical trials with VasoCare

New agreement reached for Searle's Maxaquin

AnorMED receives funding for cancer imaging

SIBIA Neurosciences initiates clinical trials of antiparkinsonian product

Immunotherapy cancer vaccine in phase II

Athena Neurosciences and Lilly extend research collaboration

Glaxo Wellcome discovers potent, selective CCK-B/gastrin antagonist

Novel kappa-opioid agonist from Parke-Davis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...